Treatment
Oxaliplatin clinical trials
We’re tracking 279 recruiting studies that include Oxaliplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT07385703RecruitingPhase 3
A trial of LM-302 with tislelizumab for stomach cancer
This trial tests a new drug combination for stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if adding LM-302 to standard treatments helps people whose tumors have a specific protein called CLDN18.2.
Hefei, AnhuiAges 18 years+ - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+ - NCT07056777RecruitingPhase 1/Phase 2
DR30206 plus standard therapy for advanced GI cancer
This trial tests a new drug called DR30206 combined with standard therapy for advanced gastrointestinal cancers. It may be an option if you have colorectal, esophageal, gastric, or gastroesophageal junction cancer and have had little or no prior chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07451652RecruitingPhase 2
Low dose epcoritamab plus chemotherapy for relapsed lymphoma
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
Monterrey, Nuevo LeónAges 18–65 - NCT07474103Recruiting
Chemo, radiation, and immunotherapy for high-risk rectal cancer
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
WuhanAges 18–75 - NCT07532902RecruitingPhase 1
Testing an experimental drug with standard care for solid tumors
This trial tests a new drug (BMS-986504) combined with standard chemotherapy or immunotherapy for three types of advanced solid tumors: mesothelioma, gastroesophageal cancer, or bladder cancer. It may be an option if your tumor has a specific genetic change called MTAP deletion.
Basking Ridge, New JerseyAges 18 years+ - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT07492615RecruitingPhase 2
Sintilimab plus chemo vs. chemo alone for stomach cancer after surgery
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07503756RecruitingPhase 2
JS212 Combination for Untreated Metastatic Colorectal Cancer
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07561060RecruitingPhase 1/Phase 2
Immunotherapy plus chemotherapy for early rectal cancer
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07562711RecruitingPhase 2
Blood Test to Guide Chemotherapy After Colon Cancer Surgery
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
ShanghaiAges 18–80 - NCT07655024RecruitingPhase 2
TAIC plus FOLFOX for advanced stomach cancer
This trial tests a traditional Chinese medicine (TAIC) combined with chemotherapy (FOLFOX) for people with advanced stomach or gastroesophageal junction cancer that can't be removed with surgery. It aims to see if the combination can help shrink the tumor and improve survival.
BeijingAges 18 years+ - NCT07356466Enrolling by invitationEarly Phase 1
Combination therapy vs. standard chemo for advanced stomach cancer
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Fuzhou, FujianAges 18–75
Common questions
- Are there clinical trials studying Oxaliplatin?
- Yes. Clin2 currently lists 279 recruiting studies that include Oxaliplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Oxaliplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Oxaliplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Oxaliplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.